These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 30243783)

  • 1. Identification of cartilage oligomeric matrix protein as biomarker predicting abatacept response in rheumatoid arthritis patients with insufficient response to a first anti-TNFα treatment.
    Nguyen MVC; Adrait A; Baillet A; Trocmé C; Gottenberg JE; Gaudin P
    Joint Bone Spine; 2019 May; 86(3):401-403. PubMed ID: 30243783
    [No Abstract]   [Full Text] [Related]  

  • 2. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
    Wadström H; Frisell T; Askling J;
    JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis.
    Akiyama M; Kaneko Y; Kondo H; Takeuchi T
    Clin Rheumatol; 2016 Nov; 35(11):2829-2834. PubMed ID: 26971256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Cardiovascular Risk of Abatacept and Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis With and Without Diabetes Mellitus: A Multidatabase Cohort Study.
    Kang EH; Jin Y; Brill G; Lewey J; Patorno E; Desai RJ; Kim SC
    J Am Heart Assoc; 2018 Jan; 7(3):. PubMed ID: 29367417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Bae SC
    Int J Rheum Dis; 2016 Nov; 19(11):1103-1111. PubMed ID: 26692536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of efficacy of TNF inhibitors and abatacept in patients with rheumatoid arthritis; Adjusted with propensity score matching.
    Kubo S; Nakayamada S; Nakano K; Sawamukai N; Hirata S; Hanami K; Saito K; Tanaka Y
    Clin Immunol; 2018 Jun; 191():67-74. PubMed ID: 29614335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor-α Therapy in Patients with Rheumatoid Arthritis: A US National Observational Study.
    Harrold LR; Litman HJ; Connolly SE; Kelly S; Hua W; Alemao E; Rosenblatt L; Rebello S; Kremer JM
    J Rheumatol; 2018 Jan; 45(1):32-39. PubMed ID: 29093151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world outcomes among patients with early rapidly progressive rheumatoid arthritis.
    Klink AJ; Curtice TG; Gupta K; Tuell KW; Szymialis AR; Nero D; Feinberg BA
    Am J Manag Care; 2019 Oct; 25(10):e288-e295. PubMed ID: 31622068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study.
    Hashimoto M; Furu M; Yamamoto W; Fujimura T; Hara R; Katayama M; Ohnishi A; Akashi K; Yoshida S; Nagai K; Son Y; Amuro H; Hirano T; Ebina K; Uozumi R; Ito H; Tanaka M; Ohmura K; Fujii T; Mimori T
    Arthritis Res Ther; 2018 Aug; 20(1):165. PubMed ID: 30075810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry.
    Monti S; Klersy C; Gorla R; Sarzi-Puttini P; Atzeni F; Pellerito R; Fusaro E; Paolazzi G; Rocchetta PA; Favalli EG; Marchesoni A; Caporali R
    Clin Rheumatol; 2017 Apr; 36(4):753-761. PubMed ID: 28058538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study.
    Pascart T; Philippe P; Drumez E; Deprez X; Cortet B; Duhamel A; Houvenagel E; Flipo RM
    Int J Rheum Dis; 2016 Nov; 19(11):1093-1102. PubMed ID: 27018857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retention and clinical response to abatacept in patients with rheumatoid arthritis: an Italian perspective.
    Galeazzi M; Alten R; Chartier M; Elbez Y; Fusaro E; Le Bars M; Lorenz HM; Pagano Mariano G; Muratore M; Nüßlein HG; Patanè G
    Clin Exp Rheumatol; 2018; 36(5):935-936. PubMed ID: 29600933
    [No Abstract]   [Full Text] [Related]  

  • 13. Assessing the cost-effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-TNF inadequate responders in Italy: a modelling approach.
    Cimmino MA; Leardini G; Salaffi F; Intorcia M; Bellatreccia A; Dupont D; Beresniak A
    Clin Exp Rheumatol; 2011; 29(4):633-41. PubMed ID: 21813056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can tocilizumab decrease cartilage oligomeric matrix protein levels and disease activity in patients with long-standing rheumatoid arthritis?
    Benucci M; Meacci F; Manfredi M; Gobbi FL; Infantino M; Ricci C; Sarzi-Puttini P; Atzeni F
    Curr Rheumatol Rev; 2014; 10(2):131-5. PubMed ID: 25599685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abatacept: A Review in Rheumatoid Arthritis.
    Blair HA; Deeks ED
    Drugs; 2017 Jul; 77(11):1221-1233. PubMed ID: 28608166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating Th17.1 cells as candidate for the prediction of therapeutic response to abatacept in patients with rheumatoid arthritis: An exploratory research.
    Maeda S; Osaga S; Maeda T; Takeda N; Tamechika SY; Naniwa T; Niimi A
    PLoS One; 2019; 14(11):e0215192. PubMed ID: 31747403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden.
    Gülfe A; Wallman JK; Kristensen LE
    Arthritis Res Ther; 2016 Feb; 18():51. PubMed ID: 26892115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cartilage oligomeric matrix protein level in rheumatic diseases: potential use as a marker for measuring articular cartilage damage and/or the therapeutic efficacy of treatments.
    Morozzi G; Fabbroni M; Bellisai F; Pucci G; Galeazzi M
    Ann N Y Acad Sci; 2007 Jun; 1108():398-407. PubMed ID: 17894003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.
    Genovese MC; Becker JC; Schiff M; Luggen M; Sherrer Y; Kremer J; Birbara C; Box J; Natarajan K; Nuamah I; Li T; Aranda R; Hagerty DT; Dougados M
    N Engl J Med; 2005 Sep; 353(11):1114-23. PubMed ID: 16162882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study.
    Gottenberg JE; Morel J; Perrodeau E; Bardin T; Combe B; Dougados M; Flipo RM; Saraux A; Schaeverbeke T; Sibilia J; Soubrier M; Vittecoq O; Baron G; Constantin A; Ravaud P; Mariette X;
    BMJ; 2019 Jan; 364():l67. PubMed ID: 30679233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.